Table 1 PbVac parasite clearance following administration of clinically relevant schedules and doses of selected drugs to mice
From: Pre-clinical evaluation of a P. berghei-based whole-sporozoite malaria vaccine candidate
Drug | Schedule (hpi) | Dose in humans (w) | Dose in mice (w/W) | Parasitemia at treatment initiation | Day of parasite clearance |
|---|---|---|---|---|---|
t = 0/6/24/48 | t = 0–600 mg | t = 0–64 mg/kga | Onset | 3 | |
Chloroquine | t = 6/24/48–300 mg | t = 6/24/48–32 mg/kga | ~1.5% | 2 | |
Coartem® | t = 0/8/24/36/48/60 | 80 mg ART | 8.4 mg/kg ARTa | Onset | 3 |
480 mg LMF | 50 mg/kg LMFa | ~1.5% | 3 | ||
Malarone® | t = 0/24/48 | 1 g ATV | 25 mg/kg ATVb | Onset | 3 |
400 mg PRG | 10 mg/kg PRGb | ~1.5% | 3 |
